# Evaluation of the Efficacy of Topical Ophthalmic Steroids in a Modified Conjunctival Allergen Challenge (CAC) Model

> **NCT01534195** · PHASE4 · COMPLETED · sponsor: **ORA, Inc.** · enrollment: 11 (actual)

## Conditions studied

- Allergic Conjunctivitis

## Interventions

- **DRUG:** Prednisolone Sodium Phosphate Ophthalmic Solution 1%
- **DRUG:** Tears Naturale II Ophthalmic Solution

## Key facts

- **NCT ID:** NCT01534195
- **Lead sponsor:** ORA, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-01
- **Primary completion:** 2012-02
- **Final completion:** 2012-02
- **Target enrollment:** 11 (ACTUAL)
- **Last updated:** 2019-03-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01534195

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01534195, "Evaluation of the Efficacy of Topical Ophthalmic Steroids in a Modified Conjunctival Allergen Challenge (CAC) Model". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT01534195. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*